D-BSSE spinoff identifies potent SARS-CoV-2 neutralising antibodies

In an interview with CNN Money Switzerland, the CEO of Memo Therapeutics Karsten Fischer announced the discovery and subsequent analysis of a repertoire of ultra-rare but highly neutralising antibodies isolated from the blood of COVID-19 recovered patients. The most potent candidates will be used for the development of therapeutic antibodies as well as rational vaccine strategies.